 ADC Therapeutics SA NYSE:ADCT, a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates for patients suffering from hematological malignancies and solid tumors, announced today that it will host a live conference call and webcast on Friday, June 12, 2020 at 8:30 AM EDT to highlight updated interim data from the pivotal Phase 2 trial of Lonca in patients with relapsed or refactory diffuse large B-cell lymphoma as well as interim results of a Phase 12 trial highlighting the potential to advance Lonca into earlier lines of therapy in combination therapies that will be presented at the virtual 25th Congress of the European Hematology Association EHA25. 